L6 monoclonal antibody binds prostate cancer

Prostate

Volumn 37, Issue 2, 1998, Pages 91-97

  O'Donnell, Robert T ^a,b,c   DeNardo, Sally J ^a   Shi, Xu Bao ^a,d   Mirick, Gary R ^a   DeNardo, Gerald L ^a   Kroger, Linda A ^a   Meyers, Frederick J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Radiodiagnosis and Therapy   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biodistribution; Immunotherapy; Prostate cancer; Radioimmunotherapy

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0031684808     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19981001)37:2<91::AID-PROS5>3.0.CO;2-O     Document Type: Article

References (31)

1. Wingo PA, Landis S, Ries LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA J Clin 1997;47:239-242.
2. Denis LJ, Carneiro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw, M: Goserelin acetate and flutemide vs. bilateral orchiectomy. Urology 1993;42:119-129.
3. 111indium labeled monoclonal antibody PAY 276. J Urol 1987;137:439-443.
4. Meyers FJ, DeNardo SJ, Macey D, deVere-White R, Unger M: Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Prostate 1989;14:209-220.
5. Bander NH: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin Oncol 1994;21:607-612.
6. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B: Preliminary imaging results using In-111 labeled CYT-356 (Prostascint™) in the detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759-767.
7. 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996;2:1289-1297.
8. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017-1022.
9. 90Y KC4. J Nucl Med [Suppl] 1995;36:213.
10. 2a antibody that reacts with most human carcinomas. Proc Natl Acad Sci USA 1986;83:7059-7063.
11. Adams GP, DeNardo SJ, Amin A, Kroger LA, DeNardo GL, Hellstrom I, Hellstrom KE: Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric ChL6 antibody. Antibody Immunoconj Radiophar 1992;5:81-95.
12. Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Arrufo A: Cloning and expression of the tumor associated antigen L6. Proc Natl Acad Sci USA 1992;89:3503-3507.
13. DeNardo SJ, O'Grady LF, Macey DJ, Kroger LA, DeNardo GL, Lamborn KR, Levy NB, Mills SL, Hellstrom I, Hellstrom KE: Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum [B] 1991;18:621-631.
14. Howell LP, DeNardo SJ, Levy NB, Lund J, DeNardo GL: Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study. Int J Biol Markers 1995;10:129-135.
15. DeNardo SJ, O'Grady LF, Richman CM, Goldstein DS, O'Donnell RT, DeNardo DA, Kroger LA, Lamborn KR, Hellstrom KE, Hellstrom I, DeNardo GL: Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997;17:1745-1752.
16. DeNardo SJ, Mirick GR, Kroger LA, O'Grady LF, Erickson KL, Yuan A, Lamborn KR, Hellstrom I, Hellstrom KE, DeNardo GL: The biologic window for chimeric L6 radioimmunotherapy. Cancer [Suppl] 1994;73:1023-1032.
17. DeNardo SJ, Peng JS, DeNardo GL, Mills SL, Epstein AL: Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int J Rad Appl Instrum [B] 1986;13:303-310.
18. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26-30.
19. Kaighn MF, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
20. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978:21:274-281.
21. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
22. 111In-bleomycin, and I-bleomycin in tumor bearing mice. Cancer 1977;40:2923-2929.
23. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF: Pharmacokinetics of chimeric L6 conjugated to indium-111-and yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med 1995;36:829-836.
24. Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, Hellstrom KE: Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer. J Clin Oncol 1990;8:1083-1092.
25. DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL: Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997;94:4000-1004.
26. Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J: Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36:267-273.
27. Meyn RE: Apoptosis and response to radiation: Implications for radiation therapy. Oncology 1997;11:349-356.
28. DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, Shen S, Miers LA, deVere-White RW, DeNardo GL: Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis related messenger RNA expression. Cancer Res [Suppl] 1995;55:5837-5841.
29. Winthrop MD, DeNardo SJ, Muenzer JT, Chi SG, Gumerlock PH: p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy. Cancer [Suppl] 1997;80: 2529-2537.
30. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, Shen S, Lamborn KR, Gumerlock PH, Meares CF, DeNardo GL: Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1998;39:842-849.
31. O'Donoghue JA: The impact of tumor cell proliferation in radioimmunotherapy. Cancer 1994;73:974-980.